|Title：||Recent Trends in the Examination of Antibody Drug and Food Use Inventions and Their International Comparison|
|Author：||Yasumasa SASAKI (Mr.), patent attorney|
|Publication：||Patent vol. 73, No. 6|
|Publisher：||Japan Patent Attorneys Association (JPAA)|
|Publication date：||June 2020|
|Overview：||Antibody drug inventions have sometimes been registered with no sequence limitations. We studied 400 recent patent cases and discovered that about 30% of such inventions were granted with no sequence limitations. More importantly, about 10% of the inventions were granted just by defining the antibody function, competitive antibody, or antigen (epitope). There was a trend that claims defined with the antibody function, competitive antibody, or antigen (epitope) were more accepted in Japan and Europe than in the U.S.